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A B S T R A C T
Objectives: Advances in tuberculosis (TB) vaccine development are urgently required to enhance global
disease management. We evaluated the potential of Mycobacterium tuberculosis (M. tb)-derived protein
antigens Rv0447c, Rv2957 and Rv2958c to boost BCG vaccine efﬁcacy in the presence or absence of
glucopyranosyl lipid adjuvant formulated in a stable emulsion (GLA-SE) adjuvant.
Methods: Mice received the BCG vaccine, followed by Rv0447c, Rv2957 and Rv2958c protein boosting
with or without GLA-SE adjuvant 3 and 6 weeks later. Immune responses were examined at given time
points. 9 weeks post vaccination, mice were aerosol-challenged with M. tb, and sacriﬁced at 6 and
12 weeks to assess bacterial burden.
Results: Vaccination of mice with BCG and M. tb proteins in the presence of GLA-SE adjuvant triggered
strong IFN-g and IL-2 production by splenocytes; more TNF-a was produced without GLA-SE addition.
Antibody responses to all three antigens did not differ, with or without GLA-SE adjuvant. Protein boosting
without GLA-SE adjuvant resulted in vaccinated animals having better control of pulmonary M. tb load at
6 and 12 weeks post aerosol infection, while animals receiving the protein boost with GLA-SE adjuvant
exhibited more bacteria in the lungs.
Conclusions: Our data provides evidence for developing Rv2958c, Rv2957 and Rv0447c in a heterologous
prime-boost vaccination strategy with BCG.
© 2017 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Contents
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 275
Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 275
Animals and ethical clearance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 275
Reagents and culture media . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 275
Vaccinations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 275
Splenocyte culture and analysis of T cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 276
Cytokine analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 276
Blood serum preparation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 276
Detection of antigen-speciﬁc IgG in mouse serum by ELISA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 276
Aerosol infection of mice with virulent M. tb . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 276
Statistical analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 277
Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 277
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
journal homepage: www.elsevier .com/ locate / i j id* Corresponding author.
E-mail address: Markus.Maeurer@ki.se (M. Maeurer).
http://dx.doi.org/10.1016/j.ijid.2017.01.024
1201-9712/© 2017 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
M. Rao et al. / International Journal of Infectious Diseases 56 (2017) 274–282 275Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 279
Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 281
Conﬂict of interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 281
Funding statement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 281
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 281
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 281Introduction
Tuberculosis (TB) vaccine development is a highly challenging
task, and has met with setbacks in recent years. Clinical trials
evaluating novel vaccine candidates have, however, taught the
global TB community lessons that collectively improve our
knowledge of protective, anti-TB immune responses in humans.
The most signiﬁcant observation in a majority of vaccine efﬁcacy
studies is that the existing TB vaccine, Bacille Calmette-Guérin
(BCG) appears to be at least as effective as novel candidates that
have undergone phase III clinical testing in infants.1,2 Nevertheless,
BCG vaccination appears to be variably protective against TB
meningitis in children (at least 70% protection against active TB
disease)3,4 but not against pulmonary TB in adults.5 Thus,
genetically modifying or boosting (viral-vectored, puriﬁed protein
antigens) the potency of the BCG vaccine to induce durable
memory responses in individuals is becoming a highly promising
strategy.6–8 In addition, newer strategies aiming at generating
attenuated strains of Mycobacterium tuberculosis as vaccine
candidates have also witnessed initial success.9
Host- and pathogen-related factors appear to affect the
longevity of protective immune responses conferred by vaccina-
tion against TB. The quality of the cellular immune response
(orchestrated by T cells) plays a critical role in barricading the
spread of M. tb infection from the lungs.10,11 In addition, enhanced
antibody responses directed against M. tb antigens are equally
important for controlling disseminated disease as well as
intracellular killing.12 Importantly, the nature or localisation of
M. tb antigens themselves (intracellular vs. extracellular vs.
secreted) inﬂuence the establishment of effective cellular and
humoral immune responses.13,14 Another highly inﬂuential com-
ponent in optimising vaccination strategies is the use of adjuvants.
Glucopyranosyl Lipid Adjuvant-stable emulsion (GLA-SE) is a
synthetic toll-like receptor 4 agonist formulated in a stable,
squalene oil-in-water emulsion.15 The ability of GLA-SE to drive
Th1 immune responses is well-documented,16,17 while its potential
in vaccinology has been evaluated in studies using preclinical
animal models of inﬂuenza,18 human immunodeﬁciency virus19
and TB20 infection.
We have previously reported a peptide microarray-based
screen to map humoral immune responses from healthy individu-
als as well as those with active TB directed against M. tb targets.14
In this study, CFA-synthase (UfaA1; Rv0447c) and two glycosyl-
transferases (Rv2957 and Rv2958c), which are involved in the
synthesis, transport and maintenance of glycolipids within the
mycobacterial cell wall,21–23 were also identiﬁed as novel M. tb
antigens with immunological and clinical relevance, based on
strong recognition by serum IgG antibodies from patients with TB
(for convenience, we have termed the antigens as the ‘KI-TB
antigens’). This ﬁnding spurred a series of in vitro immunological
assessment (i.e. cytokine production by T cells in whole blood to
antigenic stimulation, human leukocyte antigen (HLA)-DR binding
assays of speciﬁc epitopes in humans) with Rv0447c, Rv2957 and
Rv2958c using peripheral blood from patients with TB, persons
with latent TB infection (LTBI) and healthy individuals.24–26 The
results from these studies established that Rv0447c, Rv2957 and
Rv2958c participate in orchestrating clinically relevant immuneresponses in human TB by potentiating CD4+ and CD8+ T-cell
responses, with likely implications in protection against clinical
disease. Importantly, the BCG vaccine also expresses all three
proteins, although the Rv2958c gene is aberrantly transcribed due
to a frameshift mutation.22,23 In this study, we report the testing of
Rv0447c, Rv2957 and Rv2958c as potential novel vaccine
candidates in a preclinical mouse model of TB in terms of
immunogenicity and protective efﬁcacy.
Materials and Methods
Animals and ethical clearance
Female, wild type C56BL/6 mice (bred in-house at Karolinska
University Hospital Huddinge, Stockholm) were housed in
individually ventilated cages during the course of the study.
Animals were provided with a constant supply of clean drinking
water and fresh chow. All experimental procedures involving mice
were performed in adherence to requirements of the Swedish
Department of Agriculture (Jordbruksverket; approved ethical
permit diary number N273/13). Mice were sacriﬁced by isoﬂurane
anaesthesia and cervical dislocation. All efforts were made to
ensure minimized suffering and pain.
Reagents and culture media
Middlebrook 7H9 liquid medium supplemented with 10%
OADC, 2% glycerol and 0.05% Tween 80 (7H9 complete medium
(7H9C)) as well as Middlebrook 7H11 solid medium supplemented
with 10% OADC and 2% glycerol (7H11C) were purchased from the
Karolinska University Hospital substrate unit. RPMI Glutamax
medium, fetal bovine serum (FBS) and antibiotics for tissue culture
(penicillin/streptomycin) were purchased from Life Technologies.
Full-length recombinant M. tb proteins (Rv0447c, Rv2957 and
Rv2958c) were purchased from GenScript (Hong Kong). GLA-SE
adjuvant was purchased from the Infectious Disease Research
Institute, IDRI (Seattle, WA, USA).
Vaccinations
AERAS TB Vaccines Foundation (Rockville, MD, USA) kindly
provided seed stocks of the Mycobacterium bovis Bacille Calmette-
Guerín (BCG) Danish strain 1331. BCG was cultured in 7H9C
medium and grown to mid to late log-phase (OD600 0.6–0.8).
Mycobacterial cultures were then washed with PBS buffer
containing 0.05% Tween 80 (PBST80) and resuspended in 7H9C
medium supplemented with 16% glycerol and stored at 80 C. For
vaccinations, 6-7 week old mice were given a subcutaneous
injection of either 1 106 colony forming units (CFU) of the BCG
vaccine or phosphate-buffered saline (PBS; sham) in the scruff of
the neck. 3 weeks later, the animals were subcutaneously
immunised with a whole-protein antigen mix containing 2 mg of
each M. tb protein (R2958c + Rv2957 + Rv0447c) with or without
5 mg GLA-SE adjuvant, a highly potent TLR4 agonist.27 A second
round of protein administration (booster) was given 3 weeks after
the initial injection (with/without GLA-SE). A schematic represen-
tation of the vaccination schedule is shown below:
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The animals were sacriﬁced nine weeks after BCG priming and
two rounds of protein immunisation. Spleens were aseptically
removed, and put in separate 15 ml Falcon tubes containing RPMI
1640 medium (Life Technologies) supplemented with 10% FCS,
penicillin and streptomycin (R10 + ). Each spleen was mashed using
a sterile 70 mm cell strainer (BD) and 2 ml syringe plunger in a petri
dish to prepare single-cell suspensions. The cell strainer was then
washed with R10+, the ﬂow through transferred to the respective
15 ml Falcon tube and centrifuged at 1300 rpm for 5 minutes at
4 C. ACK lysis buffer (Life Technologies) was added to the cells, and
incubated at room temperature (RT) for 1–2 minutes. The tubes
were then ﬁlled with R10+ medium to stop the reaction, followed
by centrifugation at 1300 rpm for 5 minutes at RT. After resus-
pending and counting the cells, 2  105 splenocytes were seeded in
a 96-well round-bottom plate, and re-stimulated in vitro with 1 mg/
ml of the antigen mix (R2958c + Rv2957 + Rv0447c) for 72 hours at
37 C with 5% CO2. At the end of the incubation period, the plate
was centrifuged at 1600 rpm and the resulting supernatant
transferred to a non-sterile 96-well round-bottom plate for storage
at 20 C. The remaining cell pellets were resuspended in FACS
buffer (2% FCS in PBS) and centrifuged at 1300 rpm for 5 minutes.
This was followed by staining of the cells with the following
antibodies (each diluted at 1:200): CD4 PE-CF594 (BD Biosciences),
CD3 PerCP-Cy5.5 (BioLegend) and CD8 PE-Cy7 (BioLegend) on ice
for 15–20 minutes. After washing the stained cells, BD Cytoﬁx/
Cytoperm solution was added to them, and left to incubate on ice
for 20 minutes, followed by one wash with 1 x perm wash (BD
Biosciences). The cells were then resuspended in 1 x perm wash
containing 1:200 diluted antibodies for intracellular staining
(TNFa-FITC, IFNg-BV421, IL-2-APC; all purchased from BioLegend)
and incubated on ice for 30 minutes. After one wash with 1 x perm
wash, the stained cells were resuspended in FACS buffer, and
ﬁltered through a 35 mm cell strainer capped onto a 12  75 mm
tube (BD Biosciences). Cells were acquired on a BD FACS Aria ﬂow
cytometer (BD Biosciences) followed by analysis using FlowJo
software (Treestar Inc.).
Cytokine analysis
ELISA kits were purchased from Mabtech (IFNg and IL-2) and E-
Biosciences (TNFa), and assays for measuring cytokine content in
splenocyte cell culture supernatants were performed according to
the manufacturer’s instructions.
Blood serum preparation
Whole blood from sacriﬁced animals was collected in a
microcentrifuge tube, and left to clot at RT for 30 minutes. Thetubes were then centrifuged at 2000 rpm for 10 minutes in a
refrigerated (4 C) microcentrifuge, and the resulting serum layer
was immediately transferred to a clean capped polypropylene tube
for storage at 80 C.
Detection of antigen-speciﬁc IgG in mouse serum by ELISA.
Nunc MaxiSorp ELISA plates (ThermoFisher) were coated
with 1 mg/ml stock solution of M. tb antigens (Rv0447c, Rv2957c
or Rv2958c) prepared in PBS and incubated for 1 hour at 37 C.
The assay plate was washed 3 times with PBS-0.05% Tween 20
(PBST20) buffer, followed by blocking with the same buffer and
incubation at RT for 1 hour. After thorough washing with
PBST20 buffer, 1:100-diluted murine sera (diluted in dilution
buffer (PBS 0.1%-BSA-0.05% Tween 20)) was added to each well on
the assay plate. An 8-point serial dilution of IgG standards at a
ratio of 1:2 (1000 to 8 ng/ml) was prepared from a 1000 ng/ml
stock solution of recombinant murine IgG (Mabtech) in PBS, and
each dilution was added in duplicates to the respective wells on
the assay plate. The assay plate was then incubated for 2 hours at
RT, and washed thoroughly with PBST20 buffer. For detection,
alkaline phosphate-conjugated anti- human IgG monoclonal
secondary antibody (Mabtech) was diluted at a ratio of
1:1000 in dilution buffer and added to all wells, followed by
1-hour incubation at RT. The assay plate was then washed 5 times
with PBST20 buffer. Substrate solution (p-nitrophenyl phosphate
tablets (PNPP; ThermoFisher) dissolved in 1 x diethanolamine
substrate buffer (ThermoFisher) was added to the assay plate and
incubated for 15 minutes at RT. The enzymatic reaction was
stopped with 1N NaOH, and the optical density measured at
405 nm.
Aerosol infection of mice with virulent M. tb
Nine weeks after BCG/sham-vaccination and 2 rounds of
protein immunisation, the animals were aerosol-challenged with
100-200 CFU of virulent M. tb H37Rv using a nose-only exposure
system, as previously published.28,29 At 6 and 12 weeks post
aerosol challenge, the animals were sacriﬁced, and lungs and
spleens were aseptically removed. The organs were separately
homogenised using a sterile 70 mm cell strainer (BD) and 2 ml
syringe plunger in a petri dish containing PBS + 0.05% Tween
80 buffer. Serial dilutions of the homogenates were prepared in the
same buffer for plating onto Middlebrook 7H11 medium supple-
mented with 10% OADC (BD), 10 mg/ml ampicillin and 10 mg/ml
cycloheximide. Plates were incubated at 37 C for 3-4 weeks prior
to enumerating CFU. A schematic representation of the protection
efﬁcacy study is presented below:
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Data was graphed and analysed using the Graph Pad Prism
6 software. A p value of 0.05 or lower was considered signiﬁcant.
Results
We noticed in immunogenicity studies that BCG priming alone
was not able to induce production of IFN-g and IL-2 by splenocytesFigure 1. Immunological assessment of cytokine production by splenocytes in cult
antigens 3 and 6 weeks later, with or without GLA-SE adjuvant. 3 weeks after the seco
removed, and splenocytes were isolated. Cells were incubated with 1 ug/ml KI-TB antige
cytokine analysis by ELISA. IFN-g and IL-2 production, respectively are signiﬁcantly highe
as well as the group that received only the antigen boostwith GLA-SE, as compared to the
is signiﬁcantly higher in the group that received only the antigen boostwithout the GLA
antigen boost with GLA-SE adjuvant. Shown are the means and standard error of meanfollowing a 3-day exposure to Rv0447c, Rv2957 and Rv2958c in
vitro (Figure 1). However, with two administrations of the protein
antigens (with or without GLA-SE adjuvant), the production of
both cytokines was markedly increased (Figure 1). Interestingly,
only splenocytes from animals that received BCG alone, and those
that received the antigens alone without GLA-SE adjuvant
mounted a strong TNF-a response. Also, animals vaccinated with
BCG and boosted with Rv0447c, Rv2957 and Rv2958c inure supernatants. Mice were primed with BCG and given two boosts with KI-TB
nd boost (9 weeks post BCG priming), spleens of vaccinated mice were aseptically
n mix for a 72-hour period, after which the culture supernatants were collected for
r in the group that received BCG priming and the antigen boostwith GLA-SE adjuvant
 group which received only BCG (for priming). TNF-a production, on the other hand,
-SE antigen, as compared to the group that received BCG priming, followed by the
 (SEM) of four mice per group (Kruskal-Wallis test of means; *p < 0.05; **p < 0.01).
278 M. Rao et al. / International Journal of Infectious Diseases 56 (2017) 274–282theabsence of GLA-SE adjuvant exhibited a stronger TNF-a
response to in vitro antigen re-stimulation compared to animals
receiving the same vaccination regimen with GLA-SE adjuvant
(Figure 1). Similarly, splenocytes from animals vaccinated with the
antigens without GLA-SE adjuvant produced more TNF-a com-
pared to those receiving antigens with GLA-SE adjuvant. An
important observation at this stage of the study was that inclusion
of GLA-SE adjuvant in the protein-boosting step triggered a
preferential IFN-g and IL-2 response by splenocytes of vaccinated
animals.
Next, we wanted to determine the T-cell subset responsible
for cytokine production driven by booster vaccination with
Rv0447c, Rv2957 and Rv2958c in the presence or absence of GLA-
SE adjuvant and BCG priming. In this regard, we observed both
frequencies of cytokine-producing T cells as well as the absolute
cells counts. Boosting BCG vaccination with a combination of
Rv0447c, Rv2957 and Rv2958c with GLA-SE adjuvant led to a
general increase in functional (IFN-g+) antigen-speciﬁc CD8+ T
cell responses (Figure 2). In the absence of GLA-SE adjuvant, CD4
+ T cell responses appeared to have further increased, in
particular T cells producing IL-2 and TNF-a (Figure 2). IL-2-
producing CD8+ T cell responses also increased after boosting
with Rv0447c, Rv2957 and Rv2958c but in the absence of GLA-SE
adjuvant.0.0
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Figure 2. Analysis of CD4+ and CD8+ T-cell responses induced by BCG priming and KI
antigens 3 and 6 weeks later, with or without GLA-SE adjuvant. 3 weeks after the seco
removed, and splenocytes were isolated. Cells were incubated with 1 ug/ml KI-TB antige
which the cell pellets were collected for intracellular cytokine staining analysis (IFN-g+, I
were analysed. Shown are the means and standard error of mean (SEM) of four mice pImmunisation with the protein antigens alone (without
priming with BCG) emulated anti-Rv2957 serum IgG titres
comparable to the BCG-primed group, in the presence or absence
of GLA-SE adjuvant (Figure 3). For the recognition of Rv2958c by
serum IgG, priming the animals with BCG and boosting with the
protein antigens and GLA-SE adjuvant was superior to a heterolo-
gous prime-boost without GLA-SE adjuvant. We also observed that
the protein antigens alone are able to induce a strong serum IgG
response to Rv0447c when administered with GLA-SE adjuvant
(Figure 3). These results prompted us to conclude that Rv0447c,
Rv2957 and Rv2958c alone proved to be very immunogenic, as well
as their induction of IFN-g and IL-2, which is particularly
interesting for TB.
In the absence of GLA-SE adjuvant, vaccination with BCG + KI
antigens performed better than BCG or KI antigens alone, based on
lung CFU results obtained 6 weeks post challenge. We however
observed no differences in mycobacterial load in the spleen (Figure
4). At 12 weeks post M. tb challenge, vaccination with BCG + KI-TB
antigens continued to do better than BCG or KI-TB antigens alone in
reducing bacterial burden in the lungs, while in the spleen, it is was
effective as BCG or KI-TB antigens alone. Animals that were
vaccinated with BCG + KI-TB antigens in the presence of GLA-SE
adjuvant had sustained control of bacterial burden in the lungs and
spleen between 6 and 12 weeks post M. tb challenge in comparison0.0
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Figure 3. Detection of antigen-speciﬁc IgG in sera of vaccinated mice. Mice were primed with BCG and given two boosts with KI-TB antigens 3 and 6 weeks later, with or
without GLA-SE adjuvant. 3 weeks after the second boost (9 weeks post BCG priming), whole blood was collected and serum was prepared for detecting antigen-speciﬁc IgG
against the KI-TB antigens using an in-house ELISA method. Shown are the means and standard error of mean (SEM) of 3-4 mice per group.
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vaccination with BCG + KI-TB antigens in the presence of GLA-SE
appeared to achieve signiﬁcantly better control of bacterial burden
in the spleen at 12 weeks post M. tb challenge.
Discussion
Vaccination strategies focused on improving the BCG vaccine
form an integral component of the mainstay approaches to tackle
TB. Administering BCG as a priming agent can generate a large
repertoire of antigen-speciﬁc memory immune cells capable of
producing Th1 cytokines i.e. IFN-g, IL-2 and TNF-a or IgG
antibodies, respectively.30,31 In order to sustain this response in
the host, boosting with recombinant viral constructs expressing M.
tb antigens,1,7 or simply administering a booster shot with puriﬁed
recombinant M. tb proteins32 has been promising at early clinical
evaluation stages. There is only one BCG replacement vaccine
candidate in clinical trials, VPM1002, which incorporates superior
immunogenicity and safety in individuals,33 while a new study is
underway to test its efﬁcacy in HIV-exposed infants (Clinicaltrials.
gov identiﬁer: NCT02391415).
In the present report, we show that boosting the BCG vaccine
with recombinant M. tb proteins involved in mycobacterial cell
wall synthesis and maintenance, namely Rv0447c, Rv2957 and
Rv2958c leads to better control of M. tb burden in the lungs.
Although use of the toll-like receptor 4 agonist GLA-SE asadjuvant strongly promoted antigen-speciﬁc IFN-g production by
T cells, it did not appear to enhance the anti-TB effect of the M. tb
proteins  based on pulmonary M. tb load reduction inferior to
that of animals vaccinated with BCG alone. Interestingly, TNF-a
production by CD4 and CD8 T cells, which was more pronounced
in animals receiving the BCG vaccine and protein boost without
GLA-SE adjuvant, suggested a better control of pulmonary
bacterial load compared to animals vaccinated with BCG and
boosted with the protein antigens in the presence of GLA-SE
adjuvant. Initial control of M. tb infection certainly seems to
require TNF-a production, as seen in reactivation TB in individuals
receiving anti-TNF-a antibody therapy for rheumatoid arthri-
tis.34,35 Considering that serum IgG responses to Rv0447c,
Rv2957 and Rv2958c were not different between animals
receiving the BCG vaccine and protein boost with or without
GLA-SE, we suggest that humoral immune responses to these
antigens may not have a role to play in protecting against
pulmonary TB. The M. tb proteins in question are intracellular and
may be processed and presented via the MHC-I/II pathways,
concomitantly supporting the strong T-cell responses observed in
this study.
In general, the increase in cytokine producing antigen-
speciﬁc T-cell frequencies correlated well with the absolute
cell counts; this may reﬂect a true increase in the number of
functional immune cells induced by the vaccination approach.
Our results resonate with previous ﬁndings that high IFN-g
production by CD4 T cells after vaccination does not necessarily
Figure 4. Vaccine efﬁcacy assessment with BCG priming and KI-TB antigens without GLA-SE adjuvant. Mice were primed with BCG and given two boosts with KI-TB
antigens 3 and 6 weeks later, without GLA-SE adjuvant. 3 weeks after the second boost (9 weeks post BCG priming), mice were challenged with 100-200 CFU of virulent M. tb
H37Rv via the aerosol route. PBS-vaccinated mice were used as negative controls. At 6 and 12 weeks post challenge, the mice were sacriﬁced, and the lungs and spleens were
removed for CFU assessment. Shown are the medians of 4-6 mice per group (Mann-Whitney T-test of medians; *p < 0.05; **p < 0.01).
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model.36,37 Another interesting observation was the IL-2 produc-
tion by T cells from vaccinated mice. We noticed more IL-2 was
released into the splenocyte culture medium than retained in
the cells with GLA-SE adjuvant. However, without GLA-SE
adjuvant, more IL-2 appeared to be retained within the T cells
based on intracellular cytokine staining and ELISA, indicating
that without GLA-SE, IL-2 production may be slightly delayed.
This may not affect the protective efﬁcacy of BCG vaccination
boosted with Rv2958c, Rv2957 and Rv0447c without the GLA-SE
adjuvant, since better reduction of mycobacterial load in the
lungs was observed in the mice vaccinated with the KI-TB
antigens without the GLA-SE adjuvant. Similarly, the high
amount of IFN-g detected in the splenocyte culture supernatant
after 3 days of culture with the antigen mix and GLA-SE adjuvant
indicates that the adjuvant might accelerate IFN-g production,
suggesting at a rapid increase in systemic cytokine levels in the
vaccinated host.
We also did not observe superior advantage of GLA-SE
adjuvant in enhancing antibody responses to any of three
antigens tested. Previous work performed in our laboratory
reported induction of serum IgG antibodies from patients with TB
recognising single epitopes of Rv2957 on a peptide microarrayplatform.14 It is possible that this antigen is differentially
processed in humans as opposed to mice, in addition to the fact
that active infection with M. tb in humans may have a different
proﬁle of antigen processing and presentation compared to the
‘experimental vaccination’ in mice. Thus, the linear epitopes of M.
tb antigens recognised by IgG molecules in sera of patients with TB
is likely to differ to those occurring in mice used in these
preclinical studies.
The amount of of antigen-speciﬁc IgG in sera of mice vaccinated
with BCG + antigens (with/without GLA-SE) was not much higher
than antigen-speciﬁc IgG induced by BCG alone. In fact, the actual
concentration of IgG antibodies recognising Rv2957 (as well as
Rv2958c and Rv0447c) was induced by BCG vaccination, with and
without GLA-SE adjuvant (as compared to our studies using PBS as
the baseline control, data not shown). The presence of circulating
antigen-speciﬁc IgG indicates that Rv2958c, Rv2957 and Rv0447c
can on their own (without adjuvant) induce measurable humoral
immune responses  which is a key desirable feature of novel TB
vaccines.38
The results presented here further strengthen and are in line
with our previous reports describing the immunogenic potential
of Rv2958c, Rv2957 and Rv0447c based on human T-cell
assays,26,39,40 in terms of cellular immune activation.
Figure 5. Vaccine efﬁcacy assessment with BCG priming and KI-TB antigens with GLA-SE adjuvant. Mice were primed with BCG and given two boosts with KI-TB antigens
3 and 6 weeks later, with GLA-SE adjuvant. 3 weeks after the second boost (9 weeks post BCG priming), mice were challenged with 100-200 CFU of virulent M. tb H37Rv via the
aerosol route. PBS-vaccinated mice were used as negative controls. At 6 and 12 weeks post challenge, the mice were sacriﬁced, and the lungs and spleens were removed for
CFU assessment. Shown are the medians of 5-6 mice per group (Mann-Whitney T-test of medians; *p < 0.05; **p < 0.01).
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We show that boosting BCG priming with M. tb proteins
involved in cell wall biosynthesis (Rv2958c, Rv2957 and Rv0447c)
allows for improved control of M. tb burden in the lungs of mice
compared to BCG alone. Furthermore, our results suggest that the
M. tb antigens can be administered without an adjuvant due to the
in-built immunogenic potential of the proteins themselves. Thus,
we present evidence for further development of the KI-TB antigens
(Rv2958c, Rv2957 and Rv0447c) in a heterologous prime-boost
vaccination strategy with BCG.
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